Status:

COMPLETED

Canakinumab in Patients With COVID-19 and Type 2 Diabetes

Lead Sponsor:

University Hospital, Basel, Switzerland

Collaborating Sponsors:

Novartis

Swiss National Science Foundation

Conditions:

Coronavirus Infection

Diabetes Mellitus, Type 2

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

The purpose of this study is to evaluate whether Canakinumab has beneficial effects on patients with Type 2 diabetes mellitus and coronavirus disease 19 (COVID19).

Detailed Description

Patients with a metabolic syndrome (overweight, diabetes, hypertension) have a particularly bad outcome if infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV2). This may be explai...

Eligibility Criteria

Inclusion

  • Diagnosis of type 2 diabetes mellitus
  • Body mass index \> 25 kg/m² (overweight)
  • Hospitalized with COVID-19

Exclusion

  • Suspected or known untreated active bacterial, fungal, viral, or parasitic infection with the exception of COVID-19
  • Treatment with immunomodulators or immunosuppressant drugs, including but not limited to tocilizumab, tumor necrosis factor (TNF) inhibitors and anti-IL-17 agents within 5 half-lives or 30 days (whichever is longer) prior to randomization with the exception of anakinra which is excluded within 5 half-lives only. Note: Immunomodulators (topical or inhaled) for asthma and atopic dermatitis, and corticosteroids (any route of administration) such as dexamethasone are permitted.
  • History of hypersensitivity to canakinumab or to biologic drugs
  • Neutrophil count \<1000/mm3
  • Pregnant or nursing (lactating) women
  • Participation in another study with investigational drug within the 30 days preceding and during the present study-

Key Trial Info

Start Date :

October 23 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 17 2021

Estimated Enrollment :

116 Patients enrolled

Trial Details

Trial ID

NCT04510493

Start Date

October 23 2020

End Date

August 17 2021

Last Update

September 8 2021

Active Locations (9)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (9 locations)

1

University Medical Clinic Aarau

Aarau, Switzerland, 5001

2

University Hospital Basel

Basel, Switzerland, 4031

3

University Hospital Bern

Bern, Switzerland, 3010

4

Hopital du Jura

Delémont, Switzerland, 2800

Canakinumab in Patients With COVID-19 and Type 2 Diabetes | DecenTrialz